Evidence & regulatory context
- Mechanism
- Composite wound-dressing device (cellulose ether/PVA nanofibre + halloysite clay nanotubes + gentamicin sulfate). No ChEMBL entity for the composite; the payload gentamicin is a separate approved aminoglycoside. No ClinicalTrials.gov record for the mat or any halloysite-nanotube dressing (searched, not assumed).
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatWoundWistarTopical application to the wound
Model: Cutaneous wound in Wistar rats followed for 21 days
Incorporation of halloysite nanotubes and gentamicin sulfate into the nanofibre mats accelerated wound healing in Wistar rats, with healing observed within 2 weeks over a 21 day study. Halloysite nanotubes were non-toxic to L929 fibroblasts and promoted cell growth and proliferation, and gentamicin…
Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.
